Who is eligible for clinical trial NCT04884035?

Participants must meet protocol criteria for Lymphoma, B-Cell. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04884035 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (NCT04884035)

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Celgene

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

Who can join: Review the eligibility criteria below.

Location: Local Institution - 162 — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

Local Institution - 162 — Birmingham, Alabama
Local Institution - 154 — Scottsdale, Arizona
Local Institution - 169 — Duarte, California
Local Institution - 160 — Jacksonville, Florida
Local Institution - 161 — Marietta, Georgia
Local Institution - 159 — Kansas City, Kansas
Local Institution - 166 — Wichita, Kansas
Local Institution - 152 — Rochester, Minnesota
Local Institution - 163 — Saint Louis Park, Minnesota
Local Institution - 151 — Omaha, Nebraska
Local Institution - 170 — Charlotte, North Carolina
Local Institution - 164 — Winston-Salem, North Carolina
Local Institution - 155 — Houston, Texas
Local Institution - 168 — Murray, Utah
Local Institution - 171 — St. George, Utah
Local Institution - 501 — Adelaide, South Australia
Local Institution - 503 — Perth,
Local Institution - 702 — Athens,
Local Institution - 704 — Athens,
Local Institution - 701 — Athens,
Local Institution - 700 — Thessaloniki,
Local Institution - 605 — Skórzewo, Greater Poland Voivodeship
Local Institution - 601 — Gdansk,
Local Institution - 600 — Krakow,
Local Institution - 603 — Słomniki,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma, B-Cell

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York

Explore by condition: All Lymphoma, B-Cell clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗